Wave Life Sciences to Present at Upcoming Investor Conferences
Rhea-AI Summary
Wave Life Sciences (Nasdaq: WVE) announced participation in two June 2026 investor conferences.
- Jefferies Global Healthcare Conference: June 3, 2026, fireside chat at 10:30 a.m. ET.
- Goldman Sachs 47th Annual Global Healthcare Conference: June 8, 2026, fireside chat at 8:00 a.m. ET.
Live webcasts and limited-time replays will be available on Wave’s investor relations site under Investor Events.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – WVE
On the day this news was published, WVE declined 4.86%, reflecting a moderate negative market reaction. Argus tracked a trough of -2.5% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $62M from the company's valuation, bringing the market cap to $1.21B at that time.
Data tracked by StockTitan Argus on the day of publication.
CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that members of Wave’s management team are scheduled to participate in two upcoming investor conferences in June.
2026 Jefferies Global Healthcare Conference
Date: Wednesday, June 3, 2026
Details: Paul Bolno, MD, MBA, President and CEO, will participate in an analyst-led fireside chat at 10:30 a.m. ET
Goldman Sachs 47th Annual Global Healthcare Conference
Date: Monday, June 8, 2026
Details: Dr. Bolno will participate in an analyst-led fireside chat at 8:00 a.m. ET
Live webcasts of the presentations can be accessed by visiting “Investor Events” on the Investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. Replays of these presentations will be archived and available on the site for a limited time following the event.
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.
Contact:
Kate Rausch
VP, Corporate Affairs and Investor Relations
+1 617-949-4827
Investors:
James Salierno
Director, Investor Relations
+1 617-949-4043
InvestorRelations@wavelifesci.com
Media:
Katie Sullivan
Senior Director, Corporate Communications
+1 617-949-2936
MediaRelations@wavelifesci.com
